[ad_1]

WUXI, China, Oct. 1, 2023 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner, Amicus Therapeutics (“Amicus”) (Nasdaq: FOLD), on receiving U.S. FDA’s approval for…

[ad_2]